IDSA/SHEA Clostridium difficile Infection - 2018 Update

Clostridium Difficile Infection - 2018 Update

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/55729

Contents of this Issue

Navigation

Page 11 of 15

12 Treatment Table 3. Recommendations for the Treatment of C. difficile Infection (CDI) in Adults Clinical Definition Supportive Clinical Data Recommended Treatment a Strength- Quality Initial episode, non-severe Leukocytosis with a white blood cell count of <15,000 cells/mL and a serum creatinine level <1.5 mg/dL Vancomycin 125 mg given qid for 10 days, OR S-H Fidaxomicin 200 mg given bid for 10 days S-H Alternate if above agents are unavailable: Metronidazole, 500 mg tid PO for 10 days W-H Initial episode, severe b Leukocytosis with a white blood cell count of ≥15,000 cells/mL or a serum creatinine level >1.5 mg/dL Vancomycin, 125 mg qid PO for 10 days, OR S-H Fidaxomicin 200 mg given bid for 10 days S-H Initial episode, fulminant Hypotension or shock, ileus, megacolon Vancomycin, 500 mg qid PO or by nasogastric tube. If ileus, consider adding rectal instillation of vancomycin. Intravenously administered metronidazole (500 mg q8h) should be administered together with oral or rectal vancomycin particularly if ileus is present. S-M (oral vanco) W-L (rectal vanco) S-M (intravenous metro)

Articles in this issue

view archives of IDSA/SHEA Clostridium difficile Infection - 2018 Update - Clostridium Difficile Infection - 2018 Update